#3050
Radioembolization for Neuroendocrine Liver Metastases: An Institutional Case Series, Systematic Review and Meta-Analysis
Introduction:
Neuroendocrine liver metastases are clinically challenging and often non-resectable due to their frequent disseminated distribution. Radioembolisation with yttrium-90 labelled microspheres represents an emerging modality for NELM.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Clift A
Authors:
Clift A,
Frilling A,
Braat A,
Alsafi A,
Wasan H,
Keywords:
liver,
metastases,
radioembolization,
yttrium,
selective internal radiation therapy,
#2731
177Lu-DOTATATE Plus 166Ho-Radioembolization in Patients with Neuroendocrine Tumours; A Single Center, Prospective, Interventional, Non-Comparative, Open Label, Phase II Study (HEPAR PLuS Study)
Introduction:
The liver is the most commonly affected organ in metastatic neuroendocrine disease and is the most incriminating factor for patient survival. Additional treatment of liver disease with radioembolization may improve outcome in NET patients with bulky residual liver disease after PRRT.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Braat A
Authors:
Braat A,
Rutger B,
Van Rooij R,
Braat M,
Wessels F,
Keywords:
NET,
PRRT,
SIRT,
Radioembolization,
Ho-166,
Neuroendocrine tumor,
#2252
Safety and Efficacy of TAE and SIRT in NET Patients
Introduction:
Transarterial embolization (TAE) and Selective Internal Radiation Therapy (SIRT) are used for treating patients with liver metastases of a neuroendocrine tumour (NET). However, the safety and effectiveness of TAE and SIRT have scarcely been compared.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Authors:
Van Veenendaal L,
Braat A,
Meier M,
Samsom K,
Verbeek W,
Keywords:
neuroendocrine tumor,
liver metastases,
therapy,
radioembolization,
transarterial embolization,
safety,
efficacy,
#2023
International Multicentre Retrospective Study on the Safety of Radioembolization with Yttrium-90 Resin Microspheres after Systemic Radionuclide Therapy in Neuroendocrine Tumors
Introduction:
In the treatment metastatic neuroendocrine tumours (mNET) safety concerns exist when treating patients with radioembolization (RE) after prior systemic radionuclide therapy (SRT)
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Braat A
Authors:
Braat A,
Kappadath C,
Ahmadzadehfar H,
Stothers C,
Deroose C,
Keywords:
PRRT,
Radioembolization,
neuroendocrine tumors,
metastasis,
radionuclide treatments,
